<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21613" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Familial Hypocalciuric Hypercalcemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nava Suarez</surname>
            <given-names>Corina C.</given-names>
          </name>
          <aff>Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kathuria</surname>
            <given-names>Pranay</given-names>
          </name>
          <aff>Un of Oklahoma College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Corina Nava Suarez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pranay Kathuria declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21613.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Familial hypocalciuric hypercalcemia (FHH) is a genetic condition that occurs as a result of mutations in the calcium-sensing receptor gene leading to decreased receptor activity. FHH is characterized by mild hypercalcemia and is typically found in otherwise healthy and asymptomatic individuals. While most FHH patients remain asymptomatic, those with symptoms may experience fatigue, weakness, constipation, polyuria, polydipsia, or headaches.&#x000a0;The hallmark of FHH is an altered calcium-sensing mechanism that makes the parathyroid glands less sensitive to calcium. This requires a higher serum calcium level to suppress parathyroid hormone release, leading to increased&#x000a0;calcium and magnesium&#x000a0;reabsorption in the kidneys. Parathyroid hormone level is normal or mildly elevated, which can cause FHH to be confused with primary hyperparathyroidism.</p>
        <p>Diagnostic evaluation usually includes clinical assessment, laboratory studies, and genetic testing.&#x000a0;Treatment mainly involves patient education and reassurance, with calcimimetic medications (eg,&#x000a0;bisphosphonates) used in more symptomatic cases, despite not being FDA-approved for FHH.&#x000a0;This activity for healthcare professionals is designed to enhance the learner's competence in familial hypocalciuric hypercalcemia diagnosis and implementation of an appropriate interprofessional approach when managing this condition.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical features of familial hypocalciuric hypercalcemia.</p></list-item><list-item><p>Evaluate patients with presentations consistent with familial hypocalciuric hypercalcemia.</p></list-item><list-item><p>Implement the recommended management for patients with familial hypocalciuric hypercalcemia.</p></list-item><list-item><p>Apply interprofessional team strategies to improve care coordination and outcomes in&#x000a0;patients affected by familial hypocalciuric hypercalcemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21613&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21613">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21613.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Familial hypocalciuric hypercalcemia (FHH) is a genetic condition characterized by mild hypercalcemia, typically found in otherwise healthy and asymptomatic individuals. Hypercalcemia is a common cause for referral and evaluation in medicine commonly encountered in routine serum chemistry. Differential diagnoses of hypercalcemia are usually based on the acuity and severity of presentation and concomitant level of serum parathyroid hormone (PTH).&#x000a0;FHH arises from calcium-sensing receptor gene (<italic toggle="yes">CASR</italic>) mutations, leading to decreased receptor activity in response to serum calcium levels. This results in mild hypercalcemia, hypocalciuria, hypermagnesemia, and hypophosphatemia, with normal or slightly elevated serum PTH levels.</p>
        <p>FHH is usually benign and lacks the severe long-term consequences associated with other hypercalcemia syndromes. The condition's hallmark is an altered calcium-sensing mechanism, making the parathyroid glands less sensitive to calcium and requiring a higher serum calcium level to suppress PTH release. Increased calcium and magnesium reabsorption in the kidneys can also result.<xref ref-type="bibr" rid="article-21613.r1">[1]</xref><xref ref-type="bibr" rid="article-21613.r2">[2]</xref>&#x000a0;</p>
        <p>Diagnosing FHH can be challenging due to its overlap with primary hyperparathyroidism (PHPT). Diagnostic evaluation usually includes family history, serum chemistry records, and 24-hour urine calcium excretion measurement. A calcium clearance to creatinine clearance ratio (Ca/Cr) of &#x0003c;0.01 is indicative of FHH in most cases. Genetic testing for <italic toggle="yes">CASR</italic> mutations is recommended in ambiguous cases.&#x000a0;While most FHH patients remain asymptomatic, those with symptoms may experience fatigue, weakness, constipation, polyuria, polydipsia, or headaches. FHH typically does not increase fracture risk, although there have been reports of intrauterine bone abnormalities, chondrocalcinosis, and pancreatitis in some patients. Treatment mainly involves patient education and reassurance, with calcimimetic medications like Cinacalcet-HCL or bisphosphonates used in more symptomatic cases despite not being FDA-approved for FHH.</p>
      </sec>
      <sec id="article-21613.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The <italic toggle="yes">CASR</italic>&#x000a0;gene is essential in calcium homeostasis and helps maintain a physiological level of ionized calcium in the blood by managing PTH secretion.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref>&#x000a0;In most cases, familial hypocalciuric hypercalcemia (FHH) type 1 results from a loss-of-function, heterozygous mutation in the <italic toggle="yes">CASR</italic>&#x000a0;gene on the long arm of chromosome 3.<xref ref-type="bibr" rid="article-21613.r4">[4]</xref><xref ref-type="bibr" rid="article-21613.r3">[3]</xref><xref ref-type="bibr" rid="article-21613.r2">[2]</xref>&#x000a0;Those with a homozygous mutation can have severe hypercalcemia with marked neonatal hyperparathyroidism, bone fractures, and failure to thrive.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref><xref ref-type="bibr" rid="article-21613.r4">[4]</xref>&#x000a0;More rare cases of familial hypocalciuric hypercalcemia, including FHH type 2 and FHH type 3, are linked to a mutation on chromosome 19.<xref ref-type="bibr" rid="article-21613.r5">[5]</xref><xref ref-type="bibr" rid="article-21613.r6">[6]</xref><xref ref-type="bibr" rid="article-21613.r7">[7]</xref>&#x000a0;Most recently,&#x000a0;associations have been described between loss-of-function mutation on the <italic toggle="yes">GNA11</italic> and missense mutation in the <italic toggle="yes">AP2S1</italic> gene with FHH type 2 and FHH type 3, respectively.<xref ref-type="bibr" rid="article-21613.r8">[8]</xref>&#x000a0;In exceptional circumstances, FHH can rarely be caused by autoantibodies directed against the calcium-sensing receptor, leading to decreased <italic toggle="yes">CASR</italic>&#x000a0;activity, and should&#x000a0;be considered in patients with a strong family history of autoimmune disorders and no other known cause for clinical findings.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref><xref ref-type="bibr" rid="article-21613.r9">[9]</xref></p>
      </sec>
      <sec id="article-21613.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>FHH is a rare disease inherited in an autosomal dominant pattern and is equally distrib&#x000ad;uted between sexes. FHH has been estimated to be present in 1 in 10,000 to 100,000 individuals, but its prevalence is likely higher&#x000a0;given&#x000a0;its subclinical nature and challenges to differentiate FHH from PHPT.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21613.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p><italic toggle="yes">CASR</italic>-expressing tissues include the parathyroid glands, kidneys, bone, thyroidal C cells, and enterocytes.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref><xref ref-type="bibr" rid="article-21613.r10">[10]</xref><xref ref-type="bibr" rid="article-21613.r11">[11]</xref>&#x000a0;In the parathyroid gland's chief cells, the <italic toggle="yes">CASR</italic>&#x000a0;controls the synthesis and release of PTH. The <italic toggle="yes">CASR</italic>&#x000a0;is expressed in all nephron segments and affects calcium reabsorption in the kidney.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref>&#x000a0;PTH is released from the parathyroid gland when ionized calcium is decreased, leading to increased tubular calcium reabsorption. Hypercalcemia suppresses PTH release and enhances urinary excretion of calcium, sodium chloride, and magnesium independent of PTH and calcitonin levels.<xref ref-type="bibr" rid="article-21613.r10">[10]</xref></p>
        <p>The loss of function mutations in the <italic toggle="yes">CASR</italic>&#x000a0;gene in the parathyroid gland increases the set point for calcium sensing. This makes the parathyroid glands less sensitive to calcium, and a higher-than-normal serum calcium level is required to reduce the PTH release. In the kidney, this defect increases tubular calcium and magnesium reabsorption, resulting in hypercalcemia, hypocalciuria, and frequently high normal levels of serum magnesium.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref></p>
      </sec>
      <sec id="article-21613.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients with FHH type 1 are usually asymptomatic or have very few symptoms associated with mild hypercalcemia.<xref ref-type="bibr" rid="article-21613.r12">[12]</xref>&#x000a0;When symptoms are present, they tend to be nonspecific; patients may report fatigue, weakness, constipation, polyuria, polydipsia, or headaches.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref><xref ref-type="bibr" rid="article-21613.r4">[4]</xref>&#x000a0;However, patients with FHH type 3 tend to be more symptomatic, even presenting with hypophosphatemia and osteomalacia in some circumstances.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref></p>
        <p>Normally, the incidence of fractures in FHH type 1 is not increased. Nonetheless, fractures and osteoporosis can still occur.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref><xref ref-type="bibr" rid="article-21613.r13">[13]</xref>&#x000a0;Intrauterine bone abnormalities within the same family have also&#x000a0;been described in the literature, as well as chondrocalcinosis.<xref ref-type="bibr" rid="article-21613.r14">[14]</xref><xref ref-type="bibr" rid="article-21613.r15">[15]</xref><xref ref-type="bibr" rid="article-21613.r16">[16]</xref>&#x000a0;Davis et al reported patients&#x000a0;presenting with pancreatitis,&#x000a0;but causation has not been established.<xref ref-type="bibr" rid="article-21613.r17">[17]</xref><xref ref-type="bibr" rid="article-21613.r18">[18]</xref>&#x000a0;Case reports of children presenting with nephrotic syndrome have also been noted.<xref ref-type="bibr" rid="article-21613.r19">[19]</xref></p>
      </sec>
      <sec id="article-21613.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing FHH can be challenging as the clinical features of FHH and PHPT overlap; however, differentiation between both entities is critical to ensuring adequate management. Obtaining a complete clinical history, including family medical history, is the first step in evaluating FHH. Previous medical records should be reviewed for documented hypercalcemia in serum laboratory testing to establish chronicity and offer guidance since asymp&#x000ad;tomatic hypercalcemia before the age of 40 usually suggests&#x000a0;FHH.<xref ref-type="bibr" rid="article-21613.r1">[1]</xref>&#x000a0;</p>
        <p>Clinical features suggestive of FHH include a lack of typical&#x000a0;hypercalcemic symptoms, mildly elevated calcium level with an "inappropriately" normal or mildly elevated PTH level, a family his&#x000ad;tory of hypercalcemia, or a personal or family history of failed neck exploration.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref><xref ref-type="bibr" rid="article-21613.r1">[1]</xref>&#x000a0;However, some patients can present with frank hypercalcemia and elevated PTH.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref><xref ref-type="bibr" rid="article-21613.r20">[20]</xref></p>
        <p>An&#x000a0;important diagnostic tool to differentiate FHH from PHPT is the measurement of 24-hour urine calcium excretion with low urinary calcium (&#x0003c;200 mg/24 hours) despite hypercalcemia.<xref ref-type="bibr" rid="article-21613.r1">[1]</xref><xref ref-type="bibr" rid="article-21613.r20">[20]</xref>&#x000a0;The calcium clearance to creatinine clearance ratio (or Ca/Cr excretion ratio) is also used to differentiate FHH from PHPT, with a very low value of &#x0003c;0.01 pointing to FHH in 80% to 90% of cases.<xref ref-type="bibr" rid="article-21613.r1">[1]</xref><xref ref-type="bibr" rid="article-21613.r3">[3]</xref><xref ref-type="bibr" rid="article-21613.r21">[21]</xref>&#x000a0;About 10% of sporadic PHPT can also have a Ca/Cr ratio of &#x0003c;0.01.<xref ref-type="bibr" rid="article-21613.r22">[22]</xref>&#x000a0;Screening for genetic mutations in all patients with a calcium/creatinine clearance ratio of &#x02264;0.020 has been suggested.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref><xref ref-type="bibr" rid="article-21613.r23">[23]</xref></p>
        <p>Differentiation between FHH and PHPT is even more challenging in the absence of family history, when PTH levels are normal, or if the Ca/Cr clearance ratio is &#x0003e;0.01 but &#x0003c;0.02.<xref ref-type="bibr" rid="article-21613.r21">[21]</xref>&#x000a0;Even though the age at which hypercalcemia is diagnosed and the family history can guide the final diagnosis, de novo mutations can occur in approximately 15% of FHH cases; absent family history does not necessarily exclude the diagnosis.<xref ref-type="bibr" rid="article-21613.r21">[21]</xref></p>
        <p>Other causes of hypocalciuria should be excluded and corrected if present before urinary calcium is assessed. Vitamin D deficiency, an extremely insufficient calcium intake, renal&#x000a0;disease,&#x000a0;and treatment with thiazide diuretics or lithium can also falsely decrease urinary calcium levels.<xref ref-type="bibr" rid="article-21613.r22">[22]</xref><xref ref-type="bibr" rid="article-21613.r24">[24]</xref>&#x000a0;Another cation, the serum magnesium, is usually in the upper-normal range or mildly elevated in patients with FHH,&#x000a0;while the PHPT is usually associated with a low magnesium level.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref><xref ref-type="bibr" rid="article-21613.r22">[22]</xref></p>
      </sec>
      <sec id="article-21613.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Because FHH is usually a benign disorder and, for the most part, patients do not develop complica&#x000ad;tions, education and&#x000a0;reassurance of the patient and all affected family members is&#x000a0;very important and usually enough to manage FHH.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref>&#x000a0;Rarely, in a patient with atypical features and complications, sub-total parathyroidec&#x000ad;tomy may be indicated.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref></p>
        <p>The <italic toggle="yes">CASR</italic> itself is a potential therapeutic target in more&#x000a0;symptomatic cases. Calcimimetic medications, like Cinacalcet-HCL, have been successfully used in adults and children to stimulate the <italic toggle="yes">CASR</italic>, mitigating and even sometimes resolving hypercalcemia.[25][26][27] Bisphosphonates have also been used to control hypercalcemia; however, given the chronicity of FHH, they are likely to need repetitive dosing.<xref ref-type="bibr" rid="article-21613.r25">[25]</xref>&#x000a0;Clinicians should be aware that the Food and Drug Administration (FDA) has not approved these therapies for treating FHH.</p>
      </sec>
      <sec id="article-21613.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>FHH should be differentiated from other causes of PTH-dependent hypercalcemia, particularly PHPT. Both PHPT and FHH have elevated serum calcium levels with either inappropriately normal or high serum parathyroid levels; however, PHPT tends to have higher calcium and PTH levels than typically observed with FHH. PHPT is associated with increased urinary calcium, low serum phosphorus, and low magnesium levels. If left untreated, patients are almost certain to develop complications, including constipation, dehydration, nephrolithiasis, chronic kidney disease, and secondary osteoporosis with fractures, to mention some.&#x000a0;</p>
        <p>FHH can also be hard to differentiate from other etiologies of low urinary calcium, although some might not usually share a high serum calcium level. Poor oral calcium intake and low vitamin D levels can present with low urine calcium and compensatory secondary hyperparathyroidism. Thiazide diuretics decrease renal calcium excretion and may cause mild hypercalcemia, which can sometimes unmask FHH or mild PTHP; however, in normal individuals, PTH levels will be suppressed.</p>
        <p>Chronic kidney disease can present a unique challenge,&#x000a0;as it can&#x000a0;have high PTH levels, high calcium levels, and low urinary calcium if&#x000a0;tertiary hyperparathyroidism has developed&#x000a0;or if iatrogenic hypercalcemia occurs during the treatment of secondary hyperparathyroidism.<xref ref-type="bibr" rid="article-21613.r26">[26]</xref><xref ref-type="bibr" rid="article-21613.r27">[27]</xref></p>
      </sec>
      <sec id="article-21613.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In most cases, FHH has a benign disease course and a favorable prognosis with no&#x000a0;associated long-term effects, as seen in other hypercalcemia syndromes.<xref ref-type="bibr" rid="article-21613.r1">[1]</xref></p>
      </sec>
      <sec id="article-21613.s11" sec-type="Complications">
        <title>Complications</title>
        <p>In the rare cases of homozygous mutation, FHH can present as severe neonatal hyperparathyroidism. Typically, homozygous FHH presents within the first 6 months of life and has features more characteristic of severe PTH-mediated hypercalcemia than FHH. Abnormally high calcium levels can cause dehydration from polyuria; other symptoms can include hypotonia, failure to thrive, and bone changes further complicated by fractures.<xref ref-type="bibr" rid="article-21613.r3">[3]</xref>&#x000a0;Fetal intrauterine bone abnormalities in families have also been reported.<xref ref-type="bibr" rid="article-21613.r14">[14]</xref></p>
        <p>In some circumstances, adults can also&#x000a0;develop complications from hypercalcemia, especially when levels are moderate to severely elevated (serum calcium &#x0003e;12 mg/dL). Documented complications in the literature include fractures, chondrocalcinosis, nephrolithiasis, arrhythmias, and even pancreatitis.<xref ref-type="bibr" rid="article-21613.r2">[2]</xref><xref ref-type="bibr" rid="article-21613.r15">[15]</xref><xref ref-type="bibr" rid="article-21613.r16">[16]</xref><xref ref-type="bibr" rid="article-21613.r25">[25]</xref></p>
      </sec>
      <sec id="article-21613.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>FHH is a rare genetic condition that causes high calcium levels in the blood. The receptor that senses calcium levels in the body needs higher than normal calcium levels to stimulate the parathyroid glands, which release a hormone with the same name that keeps calcium levels within normal levels. FHH is usually a benign condition and, in most circumstances, is not associated with symptoms or other complications typically seen when calcium is high for prolonged periods. In rare circumstances, patients can have complications from high calcium levels, which is usually more pronounced when newborns or infants are affected. Medical treatment or surgery to remove the parathyroid glands may be necessary in patients with complications.</p>
        <p>Because FHH is a genetic condition, multiple family members within a family can be affected; therefore, clinical evaluation of blood relatives is recommended when a patient is diagnosed with FHH. Clinicians should discuss abnormal calcium levels with patients and their families and exclude more common causes of high calcium, as indicated.</p>
      </sec>
      <sec id="article-21613.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>In general, FHH is a nonprogressive benign disorder, rarely associated with complications.&#x000a0;The calcium and PTH levels are usually stable over the years. Distinguishing asymptomatic PHPT from FHH is essential, as parathyroidectomy will not routinely cure it. More challenging is to differentiate patients with atypical presentations of either disease and in the absence of family history. Family screening and education are&#x000a0;imperative to avoid unnecessary procedures for family members.&#x000a0;</p>
      </sec>
      <sec id="article-21613.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with hypercalcemia are frequently seen by nurse practitioners, primary care clinicians, and internists, often after a family member's diagnosis prompts evaluation. Healthcare professionals should be well-versed in FHH to minimize unnecessary tests and procedures. An interprofessional approach is essential, involving endocrinologists for atypical cases and, in rare instances, surgeons for potential parathyroidectomy. Pharmacists are vital in managing medications such as calcimimetic agents or bisphosphonates for severe cases. Geneticists should evaluate patients and their families to confirm the diagnosis, while pediatricians should assess affected children. Effective interprofessional communication and care coordination enhance patient-centered care, improve outcomes, ensure patient safety, and optimize team performance by avoiding redundant and costly monitoring and interventions.</p>
      </sec>
      <sec id="article-21613.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21613&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21613">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/familial-hypocalciuric-hypercalcemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21613">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21613/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21613">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21613.s16">
        <title>References</title>
        <ref id="article-21613.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Law</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families.</article-title>
            <source>Ann Intern Med</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>511</fpage>
            <page-range>511-9</page-range>
            <pub-id pub-id-type="pmid">3977197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Shoback</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Familial hypocalciuric hypercalcemia and related disorders.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>609</fpage>
            <page-range>609-619</page-range>
            <pub-id pub-id-type="pmid">30449544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>The calcium-sensing receptor in normal physiology and pathophysiology: a review.</article-title>
            <source>Crit Rev Clin Lab Sci</source>
            <year>2005</year>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-70</page-range>
            <pub-id pub-id-type="pmid">15697170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Trump</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wooding</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Besser</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism.</article-title>
            <source>J Clin Invest</source>
            <year>1995</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>2683</fpage>
            <page-range>2683-92</page-range>
            <pub-id pub-id-type="pmid">8675635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heath</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Otterud</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leppert</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity.</article-title>
            <source>Am J Hum Genet</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>193</fpage>
            <page-range>193-200</page-range>
            <pub-id pub-id-type="pmid">8317484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lloyd</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Pannett</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Thakker</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13.</article-title>
            <source>Am J Hum Genet</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>189</fpage>
            <page-range>189-95</page-range>
            <pub-id pub-id-type="pmid">9915958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michigami</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Disorders Caused by Mutations in Calcium-Sensing Receptor and Related Diseases.].</article-title>
            <source>Clin Calcium</source>
            <year>2017</year>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>521</fpage>
            <page-range>521-527</page-range>
            <pub-id pub-id-type="pmid">28336828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szalat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shpitzen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zalmon Koren</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shilo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripto-Shkolnik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Durst</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leitersdorf</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meiner</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.</article-title>
            <source>Endocrine</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>741</fpage>
            <page-range>741-747</page-range>
            <pub-id pub-id-type="pmid">28176280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallais</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Bergwitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kantham</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Slovik</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Weetman</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>672</fpage>
            <page-range>672-80</page-range>
            <pub-id pub-id-type="pmid">21159843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riccardi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Physiology and pathophysiology of the calcium-sensing receptor in the kidney.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>298</volume>
            <issue>3</issue>
            <fpage>F485</fpage>
            <page-range>F485-99</page-range>
            <pub-id pub-id-type="pmid">19923405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chanpaisaeng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Teerapornpuntakit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wongdee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Charoenphandhu</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Emerging roles of calcium-sensing receptor in the local regulation of intestinal transport of ions and calcium.</article-title>
            <source>Am J Physiol Cell Physiol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>320</volume>
            <issue>3</issue>
            <fpage>C270</fpage>
            <page-range>C270-C278</page-range>
            <pub-id pub-id-type="pmid">33356945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krupinova</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Almaskhanova</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Eremkina</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bibik</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Vasilyev</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Mokrysheva</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>[A series of clinical cases of familial hypocalciuric hypercalcemia syndrome].</article-title>
            <source>Probl Endokrinol (Mosk)</source>
            <year>2020</year>
            <month>Oct</month>
            <day>31</day>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>61</fpage>
            <page-range>61-69</page-range>
            <pub-id pub-id-type="pmid">33369373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Uwaifo</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous rib fractures in a black woman with familial hypocalciuric hypercalcemia.</article-title>
            <source>Med Sci Monit</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>CS102</fpage>
            <page-range>CS102-6</page-range>
            <pub-id pub-id-type="pmid">18830196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frerot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rideau-Batista</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Couderc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soltane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vargas-Poussou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hureaux</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prenatal bone abnormalities in three cases of familial hypocalciuric hypercalcemia.</article-title>
            <source>Prenat Diagn</source>
            <year>2022</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>583</fpage>
            <page-range>583-588</page-range>
            <pub-id pub-id-type="pmid">35301736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerriero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marchetta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caramaschi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Furlani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis.</article-title>
            <source>Joint Bone Spine</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>708</fpage>
            <page-range>708-10</page-range>
            <pub-id pub-id-type="pmid">19467900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alix</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guggenbuhl</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Familial hypocalciuric hypercalcemia associated with crystal deposition disease.</article-title>
            <source>Joint Bone Spine</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-2</page-range>
            <pub-id pub-id-type="pmid">25444087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klimiuk</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lumb</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Large</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Familial hypocalciuric hypercalcaemia and acute pancreatitis.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1981</year>
            <month>Mar</month>
            <day>28</day>
            <volume>282</volume>
            <issue>6269</issue>
            <fpage>1023</fpage>
            <page-range>1023-5</page-range>
            <pub-id pub-id-type="pmid">6783229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stuckey</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Gutteridge</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Familial hypocalciuric hypercalcaemia and pancreatitis: no causal link proven.</article-title>
            <source>Aust N Z J Med</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>718</fpage>
            <page-range>718-9, 725</page-range>
            <pub-id pub-id-type="pmid">2285390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Nephrotic Syndrome Complicated with Familial Hypocalciuric Hypercalcemia in an Infant: A Case Report and Comprehensive Literature Review.</article-title>
            <source>Altern Ther Health Med</source>
            <year>2024</year>
            <month>May</month>
            <day>03</day>
            <pub-id pub-id-type="pmid">38702153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heath</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>1989</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>723</fpage>
            <page-range>723-40</page-range>
            <pub-id pub-id-type="pmid">2673770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaj&#x000ed;&#x0010d;kov&#x000e1;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dvo&#x00159;&#x000e1;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moravcov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>V&#x0010d;el&#x000e1;k</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goltzman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Familial hypocalciuric hypercalcemia in an index male: grey zones of the differential diagnosis from primary hyperparathyroidism in a 13-year clinical follow up.</article-title>
            <source>Physiol Res</source>
            <year>2020</year>
            <month>Sep</month>
            <day>30</day>
            <volume>69</volume>
            <issue>Suppl 2</issue>
            <fpage>S321</fpage>
            <page-range>S321-S328</page-range>
            <pub-id pub-id-type="pmid">33094630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cetani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dinoi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pierotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pardi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Familial states of primary hyperparathyroidism: an update.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>2157</fpage>
            <page-range>2157-2176</page-range>
            <pub-id pub-id-type="pmid">38635114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christensen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heickendorff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brixen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mosekilde</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>713</fpage>
            <page-range>713-20</page-range>
            <pub-id pub-id-type="pmid">18410554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghaznavi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>The Biochemical Profile of Familial Hypocalciuric Hypercalcemia and Primary Hyperparathyroidism during Pregnancy and Lactation: Two Case Reports and Review of the Literature.</article-title>
            <source>Case Rep Endocrinol</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>2725486</fpage>
            <pub-id pub-id-type="pmid">27957351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koca</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.</article-title>
            <source>Turk J Pediatr</source>
            <year>2023</year>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>853</fpage>
            <page-range>853-861</page-range>
            <pub-id pub-id-type="pmid">37853976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palumbo</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Damiano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fazzotta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lo Monte</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lo Monte</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Tertiary hyperparathyroidism: a review.</article-title>
            <source>Clin Ter</source>
            <year>2021</year>
            <month>May</month>
            <day>05</day>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-246</page-range>
            <pub-id pub-id-type="pmid">33956045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21613.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tio</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Ilori</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Knauf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mc Causland</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Waikar</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>e281</fpage>
            <page-range>e281-e292</page-range>
            <pub-id pub-id-type="pmid">34390334</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
